Diets · Metabolic & Cardiometabolic
statin therapy decreases GLP-1
In plain terms: Do statins lower the appetite-and-blood-sugar hormone GLP-1?
Part of: 💊 statins
Yes — statins appear to lower this hormone via a gut-bile pathway, though the human evidence rests on one small study.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Atorvastatin lowered GLP-1 and worsened glucose tolerance via a Clostridium-bile-acid axis (reversible by UDCA) in a small trial. Real and interesting, but ONE 40-person study - Norwitz repeatedly inflates this to statins 'smashing GLP-1 into the floor.'
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Yaluri N, Modi S, López Rodríguez M, Stančáková A, Kuusisto J, Kokkola T, Laakso M 2015 · PLoS One | in-vitro | tested-null | low | Simvastatin impaired GLP-1-pathway-restorable insulin secretion in beta-cells; GLP-1 receptor stimulation rescued statin-suppressed secretion. |
| Thomasen M, Misiakou MA, Li SS, Rodriguez de Evgrafov MC, Lynggaard MB, Kårhus ML, Brønden A, Kornholt J, Chávez-Talavera O, Tailleux A, Staels B, Descat A, Hartmann B, Wewer Albrechtsen NJ, Rehfeld JF, Holst JJ, Vilsbøll T, Ellegaard AM, Sommer MOA, Sonne DP, Knop FK 2026 · Endocr Connect | RCT | contradicts | moderate | atorvastatin altered enterohepatic/incretin physiology (independent group) |
| Miskelly MG, Lindqvist A, Jujić A, Hamilton A, Cowan E, Raikundalia S, Dutius Andersson AM, Nergård BJ, Del Giudice R, Kryvokhyzha D, Nilsson PM, Holst JJ, Torekov SS, Lagerstedt JO, Gomez MF, Eliasson L, Mulder H, Hedenbro J, Magnusson M, Wierup N 2026 · J Clin Endocrinol Metab | animal | mixed | moderate | Rosuvastatin acutely REDUCED postprandial GLP-1 but chronic treatment raised it (direction depends on timing) |
| Bianchettin RG, Poirier P, Lopez-Jimenez F, Lavie CJ, Piché ME 2026 · Am J Cardiovasc Drugs | mechanism | supports | moderate | Narrative review: statins associated with increased insulin resistance and T2D risk; situates GLP-1/incretin among glucose-metabolism effects. |
| Barale C, Frascaroli C, Cavalot F, Russo I 2019 · Thromb Res | in-vitro | mixed | moderate | Barale 2019, 45 hypercholesterolaemic vs 20 control subjects' platelets exposed ex vivo to GLP-1 (7-36), GLP-1 (9-36) and liraglutide: HyC platelets were GLP-1 resistant, and simvastatin 40 mg/d (n=18) 'did not modify platelet sensitivity to the GLP-1 effects' - 'this impairment is not corrected by treatment with simvastatin.' GLP-1 levels not measured; off-scope. |
| Higuchi S, Izquierdo MC, Haeusler RA 2018 · Curr Opin Lipidol | mechanism | mixed | moderate | Narrative review: 'In an unexpected reciprocal manner, lowering LDL-cholesterol with statins slightly increases the risk of diabetes. Here we review the latest findings.' GLP-1 appears only for incretin drugs and chylomicrons ('endogenous GLP-1 and GLP-2 appear to be minor contributors to postprandial chylomicron production'); no statin→GLP-1 finding. Review (and off-object) — zero weight. |
| Buldak L, Machnik G, Skudrzyk E, Boldys A, Maliglowka M, Kosowski M, Basiak M, Buldak RJ, Okopien B 2022 · J Appl Biomed | in-vitro | supports | moderate | Atorvastatin reduced beta-cell insulin/proinsulin; GLP-1 agonist exenatide reversed it via PKA, implicating statin-GLP-1 axis disruption. |
| Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I 2010 · Lancet | meta-analysis | supports | high | Collaborative meta-analysis of statin RCTs: statins raised incident diabetes ~9%, indicating impaired glucose handling (insulin secretion/incretin axis). |
| Carmena R, Betteridge DJ 2019 · Curr Atheroscler Rep | mechanism | supports | moderate | Review of statin diabetogenic mechanisms: 10-12% increased new-onset diabetes via impaired insulin secretion/sensitivity, dose-dependent. |
| Galicia-Garcia U, Jebari S, Larrea-Sebal A, Uribe KB, Siddiqi H, Ostolaza H, Benito-Vicente A, Martín C 2020 · Int J Mol Sci | observational | tested-null | low | Mechanistic review: statins impair pancreatic beta-cell insulin secretion and sensitivity; impaired GLP-1/insulinotropic signaling among pathways. |
| She J, Tuerhongjiang G, Guo M, Liu J, Hao X, Guo L, Liu N, Xi W, Zheng T, Du B, Lou B, Gao X, Yuan X, Yu Y, Zhang Y, Gao F, Zhuo X, Xiong Y, Zhang X, Yu J, Yuan Z, Wu Y 2024 · Cell Metab | RCT | supports | moderate | RCT n=40: atorvastatin reduced GLP-1 & worsened glucose via gut bile-acid axis; UDCA rescued it |
| Kuang YL, Locatelli CAA, Qin Y, Zhang Y, Theusch E, Muñoz-Howell A, Sanchez G, Lu M, Nguyen MA, Yalamanchili T, Wang X, Nalula G, Mattis AN, Oni-Orisan A, Iribarren C, Krauss RM, Mulvihill EE, Medina MW 2025 · bioRxiv | in-vitro | mixed | low | iPSC RNA-seq: atorvastatin/simvastatin altered lncRNA linked to new-onset diabetes susceptibility; mechanistic context for statin glycemic effect. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.